Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Something is brewing
Sarah Howell, Chief Executive Officer of Arecor, said: "The successful completion of our AT278 Phase I clinical trial is an important milestone for Arecor. AT278 has the potential to disrupt the market for insulin treatment in people with diabetes, as the first concentrated, yet rapid acting, insulin - a critical enabler in the development of next generation miniaturised insulin delivery systems. The study had been designed to achieve PK/PD equivalence with a comparable dose of lower concentration NovoRapid®. The achievement of a superior PK/PD profile goes beyond our expectations and for that we are delighted.
Can’t buy a bean. They need to put the price up ;)
320 paid let’s see what happens today :)
Let’s see where this goes
Let’s see what Monday brings :)
Midatech said it made significant progress across several research and development programmes in the period, and achieved breakthrough data for its Q-Sphera drug capsule technology, creating "several opportunities for licensing".
"Our current funding position buys us time and flexibility to convert opportunities into licenses and we are fully focused on meeting that challenge over the coming months," the company said.
Following a GBP10.0 million share placing in June, Midatech now has enough cash to last until the first quarter of 2023, assuming no money from licensing deals. The cash balance on June 30 was GBP4.2 million.
Stephen Stamp, Midatech's chief executive and chief financial officer, said: "The first half of 2021 has been highly productive with three potentially viable Q-Sphera formulations, one internal and two for a collaboration partner.
"We believe the breakthrough data on the encapsulation of a protein could prove to be a very significant opportunity for Midatech."
Alliance News) - Safestay PLC on Friday said it will review its strategic options including a possible sale of the company, after receiving an early approach over a possible takeover.
Shares surged 21% to 24.15 pence in London at the open on Friday, giving the company a market capitalisation of GBP15.8 million.
The London-based company, which operates city centre hostels across Europe, said the strategic review would aim to maximise value for shareholders and better position itself for growth. The review will consider a sale among other options.
Safestay has received "a very early stage and highly conditional approach from a party in relation to a possible offer."
Safestay was hit hard by the pandemic, with revenue slumping 74% in 2020 and its pretax loss widening to GBP10.1 million. Since then, the firm sold its Edinburgh branch to A&O Hotels & Hostels GmbH for GBP16 million, and a leasehold site in Barcelona for EUR900,000. In addition, Safestay cut costs, renegotiated rental terms, and took part in government support schemes.
Chair Larry Lipman said: "Individual and group bookings are coming in for the winter and for 2022 and underpin our confidence of returning to pre-Covid levels of trading. We believe strongly in the appeal of the Safestay brand.
"However, we recognise that this is a natural point, as we relaunch the business post-Covid, to undertake a strategic review, in order to maximise value for all shareholders. This process will reveal whether there is additional value for shareholders compared to the upside we believe we can deliver."
Safestay has appointed PricewaterhouseCoopers as financial adviser for the strategic review and formal sale process.
They don’t know what to do with the price
Keep a hold guys let’s see what tomorrow brings :)
Sure does some big buys coming in :)
Keep holding for that 1p :)
Can’t find it anywhere
Little bit of pressure and can see this going mental!
Neither in or out :)